QUECTEL-WIRELESS
8.4.2024 10:01:34 CEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, is pleased to be showcasing some its industry leading IoT connectivity solutions and technologies, catering to various industries and applications at Embedded World 2024 in Nürnberg.
During the event, visitors can explore Quectel’s extensive portfolio of IoT modules and solutions designed to meet the diverse needs of the IoT ecosystem. From 5G and LTE-M/NB-IoT modules to GNSS positioning modules, Quectel offers a comprehensive range of products that empower businesses to build reliable, scalable, and future-proof IoT solutions.
In addition, Zeljko Maric, Product Development Manager at Quectel, will be participating in a panel session centered on IoT Modem Reference Design or IoT SoC Modules Modem for Embedded Designers. The session is scheduled to take place in the exhibitor forum, Hall 3, on Wednesday, April 10th, at 3:30 PM.
"We are excited to participate in Embedded World 2024 and showcase our latest innovations in IoT connectivity," said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "As a leading provider of IoT modules, Quectel is dedicated to empowering businesses worldwide with reliable, secure and innovative connectivity solutions. We look forward to engaging with industry peers, customers, and partners at the event."
Quectel is also highlighting some of its customers’ innovations during the show:
- Broadcast Sports International: 5G MT-UHD, an advanced 5G-enabled broadcasting tool that opens new horizons for live sports and events coverage.
- Consenz Head-up Display – equipped with the Quectel SC680A module, this cost-effective retrofit Head-Up Display (HUD) solution from Consenz enhances driving safety.
- Speed Tech Corporation /Luxshare-ict Precision 5G MiFi unit alongside their 5G Indoor CPE and 5G Outdoor CPE units.
- Microamp Solutions’ CellBox Air 5G mmWave Radio Unit is a system that connects to the Distributed Unit (DU) through the O-RAN 7.2x interface and features an integrated Massive MIMO antenna array.
- MikroTik’s Chateau 5G Router is a device that epitomizes the fusion of sophisticated design and powerful 5G connectivity, designed to cater to the growing demand for faster and more reliable home and office internet solutions.
- Monitair MonAir-CO2, a unique environmental sensor is equipped with the advanced Quectel EG915U LTE Cat1bis module and YC0002AA antenna, making it a one-of-a-kind 4G battery-operated device capable of meticulously tracking CO2, temperature, humidity, COV, NOX, and noise levels.
- Particle's M-SoM M404 M.2 system-on-module embeds multi-radio connectivity in IoT devices features LTE-M + 2G fallback + dual-band Wi-Fi and includes a high-end modern microcontroller with Arm TrustZone, secure boot, and capable of running Edge ML models, combined with a best-in-class Quectel connectivity module.
- PayEye eyePOS 3 - The world's only terminal to support iris and facial biometrics fusion and all types of cashless payments - card, contactless (NFC) and mobile, featuring the QUECTEL SC668S-EM.
- Sixfab will be showcasing a number of devices on the Quectel stand including the Jumpstart 5G, a fully certified, all-inclusive, ready-to-connect IoT computer for high-speed applications, a 4G/LTE Cellular Modem Kit for Raspberry Pi, a versatile 4G/LTE connectivity solution for Raspberry Pi and the Pico LTE, a comprehensive platform for global cellular connectivity & low-power IoT, pre-integrated with AWS IoT, Azure IoT & more.
- Ricon will be presenting the S9980DSL-LTEv2 High-Speed Fiber Optical xDSL Fixed/Wireless Router with Integrated 4.5G Cellular Interface and S9955OUT-5G Industrial Outdoor Router
- Roltek will be demonstrating their Edge Pro LTE8421 4G IOT Gateway, designed using the Quectel EG915 module to provide seamless and reliable connectivity even in challenging conditions
- ZCS Lawn Mower Robot: The ZCS autonomous lawn mower robot, powered by the Quectel LG69T Series module, an automotive grade dual-band multi-constellation GNSS module integrating DR/RTK, demonstrates the future of smart, connected landscaping.
As part of the Quectel stand, Ikotek, a leading IoT original design manufacturer (ODM), will be there to showcase its capabilities in IoT device design, manufacturing and certification delivering high quality products and services to reduce complexity, speed up time to market, eliminate risk and reduce costs.
Finally, Acceleronix, a global IoT solutions and services enablement provider primarily focused on serving OEMs and enterprises, will have a presence on the Quectel stand. Delivering edge-device management software, Connectivity-as-a-Service, specialized vertical software, and mobile applications, Acceleronix offers comprehensive solutions tailored to empower every facet of IoT product lifecycle, spanning from development to data management and visualization.
Attendees to Embedded World can find Quectel on stand 3-318.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408354948/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom